Caribou Biosciences Q4 Loss Narrows to $0.28, Revenue Surges 56% to $3.94M
Caribou Biosciences posted a Q4 adjusted loss of $0.28 per share compared with consensus estimate of a $0.33 loss, marking a 14% positive earnings surprise, while revenue rose to $3.94 million, beating estimates by 56%. Its shares have gained 13.2% year-to-date versus the S&P 500’s 0.4% return.
1. Q4 Financial Highlights
Caribou Biosciences delivered an adjusted loss of $0.28 per share for Q4, outperforming the consensus estimate of a $0.33 loss by 14.11%. Revenue climbed 89% year-over-year to $3.94 million, outpacing forecasts by 56.02% and marking the company’s second revenue beat in the past four quarters.
2. Year-to-Date Stock Performance
Following the report, Caribou Biosciences shares have risen 13.2% since January 1, significantly outshining the S&P 500’s 0.4% gain. This robust performance reflects investor optimism driven by consecutive earnings and revenue surprises.
3. Forward Estimates and Outlook
Consensus for the coming quarter stands at a $0.36 loss per share on $2.5 million in revenue, with full-year estimates at a $1.44 loss on $32.43 million in sales. Analysts will closely watch management’s commentary for guidance revisions and assessment of cost controls going forward.